Emerging Infectious Disease ISSN: 1080-6059

Model for Assessing Human Papillomavirus Vaccination Strategies

Elamin H. Elbasha*

, Erik J. Dasbach*, and Ralph P. Insinga*

Author affiliations: *Merck Research Laboratories, North Wales, Pennsylvania, USA;

Figure 6

Sensitivity analysis. A) Incidence of genital warts due to human papillomavirus (HPV) 6/11 infection among boys and men >12 years of age, by strategy, 10 years’ duration of protection. B) Incidence of genital warts due to (HPV 6/11 infection among girls and women >12 years of age by strategy, 10 years’ duration of protection.

Figure 6. Sensitivity analysis. A) Incidence of genital warts due to human papillomavirus (HPV) 6/11 infection among boys and men >12 years of age, by strategy, 10 years’ duration of protection. B) Incidence of genital warts due to (HPV 6/11 infection among girls and women >12 years of age by strategy, 10 years’ duration of protection.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.